The HIT-CF project (funded by the EU’s Horizon2020 programme) kicked off in January 2018, and aims to provide access to innovative drug candidates for CF patients with rare mutations based on the response in their organoids.

CF Europe is the work package leader for communication and dissemination. To learn more about the project, visit the HIT-CF website. Head to the news feed and newsletters for regular updates.